Teledermatology has undergone exponential growth in the past 2 decades. Many technological innovations are becoming available without necessarily undergoing validation studies for specific dermatologic applications.
T elehealth technologies have been used by dermatologists for more than 20 years to expand access to quality specialist care and augment traditional face-to-face interactions. 1 Given the exponential growth in the field of telemedicine, the validity, safety, and feasibility of promising new applications need to be ensured, especially because these applications are being used frequently in clinical research applications. The central purpose of this study was to determine whether acne scoring through digital photographs taken by a patient on an iPhone using Network Oriented Research Assistant (NORA) is accurate and reliable compared with in-person examination findings.
Methods
We performed a pilot reliability study to measure the correlation between acne assessments performed by board-certified dermatologists in face-to-face assessments and assessments made by the same dermatologists from digital patient-taken self-photographs using NORA. The Schulman Institutional Review Board approved this study, and all patients provided written informed consent. Standardized clinical research acne severity scoring used lesion counting and the Investigator's Global Assessment (IGA; scores range from 0-5, with higher scores indicating more severe disease). A period of at least 1 week separated the inperson and digital assessments of acne. This study took place in a single general dermatology practice in Los Angeles, California. Patients with acne vulgaris were enrolled consecutively from January 1 through March 31, 2016. After enrollment, study participants were trained to use NORA on an iPhone 6 to take 5 photographs of their facial acne (forehead, chin, right cheek, left cheek, and entire face). Participants were instructed to use the camera on the back of the iPhone. [7.7] years) participated in this study; patient demographic characteristics are outlined in the Table. The first 9 participants were used for prototyping the photography module and workflow; these data were not included in the analysis. The next consecutive 60 individuals underwent evaluation by a dermatologist in the office and through digital self-taken photographs with NORA. Both evaluations included a lesion count and IGA, and the data from these participants were analyzed.
Results
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We calculated the intraclass correlation coefficient (ICC) to compare the intraobserver reliability assessment outcomes from in-person examination findings and patienttaken digital photographs for the IGA and lesion counting. The ICC was adjusted for the effects of scale of measurement and can represent agreements from more than 2 raters or measuring methods. An ICC of 0 means no agreement; 1.0, perfect agreement. The ICC for the IGA was 0.75; for total lesion count, 0.81. Inflammatory lesion count, noninflammatory lesion count, and cyst count had ICCs of 0.72, 0.72, and 0.82, respectively. Overall, strong agreement was observed between assessment scores from face-to-face examinations and those from patient-taken digital photographs.
Discussion
NORA was designed and built by Science 37, Inc, as a robust technology that includes the functionality of a telemedicine platform, an electronic medical record, an electronic data capture structured database, and a mobile data collection tool. NORA can be customized and configured for different types of studies and data collection and allows participants to act remotely based on prompts. NORA is a Cloud-based platform that uses Amazon Web Services, operates securely on mobile operating system iOS devices, and is currently being used in multiple US Food and Drug Administration-regulated decentralized or siteless telemedicine-based clinical trials across several therapeutic areas.
Acne vulgaris affects nearly everyone at some point in adolescence, with as many as 20% of young adults experiencing moderate to severe acne. 2 The high prevalence and chronic nature of acne make it an ideal disease in which to validate new tools for telehealth clinical research applications, such as NORA. In addition, mobile camera technology and optics have improved significantly in recent years. Many scales have been developed to clinically grade acne based on 1 or more of the following approaches: lesion counting, global severity rating, subjective self-assessment, and imaging. A recent critical review of published acne severity scales found that 33% of studies that reported interrater reliability had ICCs of greater than 0.75 and 71% that reported intrarater reliability had ICCs of at least 0.80. compared with traditional in-person visits for a variety of conditions. [4] [5] [6] For acne in particular, the results of this study support findings from randomized clinical trials that have shown comparable outcomes for patients undergoing teledermatology and those receiving in-person treatment.
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Acne vulgaris can be a challenging disease for patient and dermatologist to manage because frequent follow-up visits are often necessary to ensure the efficacy and feasibility of treatment plans. A recent study demonstrated that monthly office visits to monitor isotretinoin treatment are a burden for patients and/or their caregivers and that most patients would be willing to pay for electronic visits as an alternative. 8 For patients who do not live in urban areas or have private insurance, the time and expense of obtaining dermatologic care is a significant barrier. Teledermatology has been shown to increase access to care among Medicaid enrollees and may be an effective tool for patient populations that are less able to attend regular dermatologic appointments. 9 
Limitations
The limitations of this study include its small size and a patient population that represents a single geographic region. Although a 1-to 2-week period separated the digital and in-person evaluations, recall bias may remain because the same dermatologist performed both assessments. Future studies with multicenter participation would address these aspects and allow for the collection of data during a longer-term follow-up. Gathering data that would support analysis of cost, time, and patient-reported measures is a goal of future studies.
Conclusions
This study demonstrates that patient-taken digital selfphotographs with NORA on a mobile device can be used to assess acne vulgaris reliably in telemedicine-based clinical trials. Given the exponential growth of telehealth and increasing options for different platforms, validation is necessary to ensure that the proper tools are used to deliver high-quality care. The NORA technology platform is currently being used in trials for atopic dermatitis, pemphigus vulgaris, cluster headache, oncologic evaluation, and liver disease. Use of the NORA platform in telemedicine-based clinical trials will allow for increased access, a broader diversity of patients, and improved adherence among participants in trials for acne vulgaris and other therapeutic areas.
